See more : Cvent Holding Corp. (CVT) Income Statement Analysis – Financial Results
Complete financial analysis of CH Biotech R&D Co., Ltd. (6534.TW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CH Biotech R&D Co., Ltd., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- Caisse Régionale de Crédit Agricole Mutuel Brie Picardie Société coopérative (CRBP2.PA) Income Statement Analysis – Financial Results
- Vialife SA (ALVIA.PA) Income Statement Analysis – Financial Results
- Dai-ichi Karkaria Limited (DAICHI.BO) Income Statement Analysis – Financial Results
- Communities First Financial Corporation (CFST) Income Statement Analysis – Financial Results
- Shandong Hi-Speed Holdings Group Limited (0412.HK) Income Statement Analysis – Financial Results
CH Biotech R&D Co., Ltd. (6534.TW)
About CH Biotech R&D Co., Ltd.
CH Biotech R&D Co., Ltd., develops and sells biotech-based agrochemicals in Taiwan, the United States, Canada, Australia, Brazil, Argentina, Uruguay, Chile, and internationally. It offers plant growth regulators and fertilizers; and biotechnology services. CH Biotech R&D Co., Ltd. was incorporated in 2013 and is headquartered in Nantou City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.51B | 1.43B | 1.02B | 702.19M | 840.68M |
| Cost of Revenue | 254.73M | 299.52M | 170.56M | 112.18M | 143.56M |
| Gross Profit | 1.26B | 1.13B | 847.95M | 590.01M | 697.12M |
| Gross Profit Ratio | 83.18% | 79.11% | 83.25% | 84.02% | 82.92% |
| Research & Development | 305.24M | 272.41M | 221.48M | 193.34M | 162.31M |
| General & Administrative | 292.25M | 265.62M | 213.85M | 190.14M | 203.14M |
| Selling & Marketing | 96.75M | 85.50M | 53.35M | 61.46M | 73.84M |
| SG&A | 389.00M | 351.12M | 267.20M | 251.60M | 276.98M |
| Other Expenses | 565.86M | 3.59M | 25.73M | 28.01M | 0.00 |
| Operating Expenses | 1.26B | 623.54M | 488.68M | 444.93M | 439.29M |
| Cost & Expenses | 1.51B | 923.06M | 659.24M | 557.12M | 582.85M |
| Interest Income | 17.22M | 5.12M | 599.00K | 1.52M | 5.46M |
| Interest Expense | 16.81M | 16.81M | 13.90M | 22.74M | 21.65M |
| Depreciation & Amortization | 165.81M | 139.68M | 96.65M | 98.20M | 88.14M |
| EBITDA | 761.56M | 722.29M | 470.20M | 248.33M | 352.05M |
| EBITDA Ratio | 50.27% | 50.33% | 46.15% | 35.36% | 41.88% |
| Operating Income | 565.86M | 582.04M | 373.44M | 150.09M | 257.83M |
| Operating Income Ratio | 37.35% | 40.59% | 36.67% | 21.38% | 30.67% |
| Total Other Income/Expenses | 13.07M | -16.25M | -13.79M | -22.70M | -15.58M |
| Income Before Tax | 578.93M | 565.80M | 359.65M | 127.39M | 242.26M |
| Income Before Tax Ratio | 38.22% | 39.45% | 35.31% | 18.14% | 28.82% |
| Income Tax Expense | 115.64M | 100.37M | 68.15M | 27.23M | 51.79M |
| Net Income | 463.29M | 465.42M | 291.50M | 100.16M | 190.47M |
| Net Income Ratio | 30.58% | 32.45% | 28.62% | 14.26% | 22.66% |
| EPS | 4.76 | 4.79 | 3.00 | 1.03 | 1.97 |
| EPS Diluted | 4.73 | 4.72 | 2.97 | 1.03 | 1.94 |
| Weighted Avg Shares Out | 97.27M | 97.08M | 97.08M | 97.08M | 97.08M |
| Weighted Avg Shares Out (Dil) | 97.87M | 98.63M | 98.10M | 97.66M | 98.03M |
Source: https://incomestatements.info
Category: Stock Reports